ORGO Stock Overview
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
Organogenesis Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.64|
|52 Week High||US$19.75|
|52 Week Low||US$5.30|
|1 Month Change||-17.06%|
|3 Month Change||-15.06%|
|1 Year Change||-65.82%|
|3 Year Change||-20.34%|
|5 Year Change||n/a|
|Change since IPO||-58.04%|
Recent News & Updates
Organogenesis Holdings: What Now
Today, we revisit advance wound care name Organogenesis Holdings for the first time since late in 2020. This small cap healthcare concern is already profitable and continues to build out its product portfolio. A full investment analysis follows in the paragraphs below.
|ORGO||US Biotechs||US Market|
Return vs Industry: ORGO underperformed the US Biotechs industry which returned -21.4% over the past year.
Return vs Market: ORGO underperformed the US Market which returned -12.3% over the past year.
|ORGO Average Weekly Movement||11.7%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ORGO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ORGO's weekly volatility (12%) has been stable over the past year.
About the Company
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications.
Organogenesis Holdings Fundamentals Summary
|ORGO fundamental statistics|
Is ORGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ORGO income statement (TTM)|
|Cost of Revenue||US$113.78m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.66|
|Net Profit Margin||18.34%|
How did ORGO perform over the long term?See historical performance and comparison
Is Organogenesis Holdings undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ORGO ($5.64) is trading below our estimate of fair value ($91.52)
Significantly Below Fair Value: ORGO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ORGO is good value based on its Price-To-Earnings Ratio (8.6x) compared to the US Biotechs industry average (14.9x).
PE vs Market: ORGO is good value based on its Price-To-Earnings Ratio (8.6x) compared to the US market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: ORGO is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: ORGO is overvalued based on its Price-To-Book Ratio (3x) compared to the US Biotechs industry average (1.5x).
How is Organogenesis Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORGO's forecast earnings growth (10.1% per year) is above the savings rate (1.9%).
Earnings vs Market: ORGO's earnings (10.1% per year) are forecast to grow slower than the US market (12.3% per year).
High Growth Earnings: ORGO's earnings are forecast to grow, but not significantly.
Revenue vs Market: ORGO's revenue (9.8% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: ORGO's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORGO's Return on Equity is forecast to be high in 3 years time
How has Organogenesis Holdings performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORGO has a high level of non-cash earnings.
Growing Profit Margin: ORGO's current net profit margins (18.3%) are higher than last year (11.5%).
Past Earnings Growth Analysis
Earnings Trend: ORGO has become profitable over the past 5 years, growing earnings by 69.9% per year.
Accelerating Growth: ORGO's earnings growth over the past year (95.6%) exceeds its 5-year average (69.9% per year).
Earnings vs Industry: ORGO earnings growth over the past year (95.6%) underperformed the Biotechs industry 96.9%.
Return on Equity
High ROE: ORGO's Return on Equity (35%) is considered high.
How is Organogenesis Holdings's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ORGO's short term assets ($217.9M) exceed its short term liabilities ($76.8M).
Long Term Liabilities: ORGO's short term assets ($217.9M) exceed its long term liabilities ($116.3M).
Debt to Equity History and Analysis
Debt Level: ORGO has more cash than its total debt.
Reducing Debt: ORGO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: ORGO's debt is well covered by operating cash flow (88.6%).
Interest Coverage: ORGO's interest payments on its debt are well covered by EBIT (11.4x coverage).
What is Organogenesis Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORGO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ORGO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gary Gillheeney (66 yo)
Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018. Mr. Gillheeney served as Organoge...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD4.43M) is about average for companies of similar size in the US market ($USD3.85M).
Compensation vs Earnings: Gary's compensation has increased by more than 20% in the past year.
Experienced Management: ORGO's management team is considered experienced (4.7 years average tenure).
Experienced Board: ORGO's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ORGO insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Organogenesis Holdings Inc.'s employee growth, exchange listings and data sources
- Name: Organogenesis Holdings Inc.
- Ticker: ORGO
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$728.294m
- Shares outstanding: 129.13m
- Website: https://organogenesis.com
Number of Employees
- Organogenesis Holdings Inc.
- 85 Dan Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.